Superstar #kidneycancer researcher Laurence Albiges showing the #CABOPOINT results for cabozantinib after ipi-nivo and VEGF-IO combos. Preserved activity in these cohorts. Kudos to careful studies in refractory #kidneycancer . ASCO #GU23 OncoAlert

Please stop by our biomarker-driven OPTIC RCC Trial-in-Progress Poster (TPS 742) lead by Brian Rini, MD Scott Haake, MD, PhD Katy Beckermann, Anupama Reddy ,Yu Shyr Kimryn Rathmell Sumanta K. Pal, MD, FASCO Tian Zhang, MD, MHS Moshe Ornstein MD Pedro C Barata, Natalia Mar Uromigos ASCO #GU23

Exciting sneak peek of advances in genitourinary cancer research coming up at #GU23 ! Stay tuned for cutting-edge findings on novel treatments, biomarkers, and more. Pushing the boundaries and improving outcomes! ⁦⁦Neeraj Agarwal, MD, FASCO⁩ dailynews.ascopubs.org/do/podcast-ara…

Excited to dive into the latest advancements in GU cancer care at #ASCOGU2023 ! Can't wait to learn from the best in the field and catch up with colleagues in the industry 💪 #Oncology #CancerCare #Advancements #ChatGPT

9/ #TumorBoardTuesday #OncTwitter #NephTwitter #BonumCE

🏃‍♀️Need to catch up on...
🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt
#ICYMI 🪡 #RenalCell #MedTweetorial 🧵👇

twitter.com/TumorBoardTues…

8/ #TumorBoardTuesday #RenalCell #NephTwitter

🔴 #PostTest Q4️⃣
🗳️ Pt treated w/ combo of cabozantinib + nivolumab develops G3 hypertension. Cabo therapy is held & pt receives anti-hypertensive medication & BP recovers to baseline. At what dose can cabozantinib be restarted?

7/ #TumorBoardTuesday #RenalCell #NephTwitter #MedTwitter #BonumCE
#CME 🔗bit.ly/3FamQyu

🔴 #PostTest Q3️⃣
🗳️ Pt treated w/ combo of pembrolizumab and lenvatinib for metastatic RCC develops grade 3 diarrhea. How might you diagnose which drug is causing this toxicity?

6/ #TumorBoardTuesday #OncTwitter #RenalCell #NephTwitter #MedTwitter #BonumCE
#CME 🔗bit.ly/3FamQyu

🔴 #PostTest Q 2️⃣
🗳️ Which of the following is NOT a characteristic of immune-mediated toxicities associated with the use of ICIs?

5/ #TumorBoardTuesday #NephTwitter #MedTwitter #BonumCE

⌛️Chat is winding down but keep the 🔥going
🏆Claim🆓 #CME 🔗bit.ly/3FamQyu
🗳️Answer polls👇

🔴 #PostTest Q1️⃣
Which is a common high-grade toxicity associated with the use of TKIs in the mgmt of mRCC?

4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter

Let’s revisit efficacy of 🔑Ph3 clin trials:
💎 #CLEAR
💎 #KEYNOTE426
💎 #CheckMate9ER
💎 #CheckMate214

3/ #TumorBoardTuesday #RCC #NephTwitter #MedTwitter #OncTwitter

🟠Earn 🆓 #CME 🏆
🟠CME ℹ️🔗bit.ly/3iLN6aX

📸 Faculty disclosures & important CME info 👇

2/ 🪂BEFORE diving in 🪂…
🔗👇open link below (right click🖱️> open in 🆕tab)
✅ Answer #PreTest polls
🔁Retweet & tag colleagues

twitter.com/TumorBoardTues…

27/ #TumorBoardTuesday #BonumCE
#OncTwitter #NephTwitter #MedTwitter

🧗Climb your next mountain ⛰️
🔥 #RenalCell Carcinoma Fireside Chat🎥🔥
🗓 Thur, Dec 15 @ 8pm ET / 5pm PT
w/ experts Brian Rini, MD Shilpa Gupta Katy Beckermann

26/ #TumorBoardTuesday #BonumCE #RenalCell

🔴 Post Poll 4️⃣
#CME ➡️ bit.ly/3W0R1Pq

Pt w mRCC
🔸Initiated tx w pembro + lenva
🔹Developed G3 diarrhea
🔸Lenva withheld & anti-diarrheal treatment initiated 🔹Diarrhea now resolved.

🔴What next step is best for the pt?

25/ #TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🔴Post Poll 3️⃣
CME➡️ bit.ly/3W0R1Pq

🔴Which of the following is an AE that is commonly observed with both ICIs and TKIs?

24/ #TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter
#CME ➡️ bit.ly/3W0R1Pq

🔴Post Poll 2️⃣
🔴Which of the following is a characteristic feature of the most common toxicities associated with anti-angiogenic therapies?

23/ #TumorBoardTues #BonumCE
Thanks for joining me & @TumorBoardTuesday

🔴Answer post-polls👇
Claim🆓 #CME 👉bit.ly/3VDaK81

🔴Post Poll 1️⃣
🔴Which of the following TKI/IO combo regimens is 🚫NOT approved by the FDA for the frontline mgmt of #RenalCell carcinoma?